Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
Items 601–700 of 899
Kyriakopoulos, G. C., Katopodi, V., Skeparnias, I., Kaliatsi, E. G., Grafanaki, K., & Stathopoulos, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042222 · Cited by 6
A forward genetic screen identifies modifiers of rocaglate responsiveness
Shen, L. L., Pugsley, L., Cencic, R., Wang, H., Robert, F., Naineni, S. K., Sahni, A., Morin, G., Zhang, W., Nijnik, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97765-8 · Cited by 6
Self-citationTranslational landscape in human early neural fate determination
Yan, C., Meng, Y., Yang, J., Chen, J., & Jiang, W. (2023) · Development · doi:10.1242/dev.201177 · Cited by 6
The FAM86 domain of FAM86A confers substrate specificity to promote EEF2-Lys525 methylation
Francis, J. W., Shao, Z., Narkhede, P., Trinh, A. T., Lu, J., Song, J., & Gozani, O. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104842 · Cited by 6
“It has been reported that translational control of the proteome, including EEF2 upregulation (14, 15), is common in human cancers (16, 17).”
BackgroundHuertas-Abril, P. V., Jurado, J., Prieto‐Álamo, M., García‐Barrera, T., & Abril, N. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.166558 · Cited by 6
McLean, D. T., Meudt, J. J., Rivera, L. D. L., Schomberg, D. T., Pavelec, D. M., Duellman, T., Buehler, D. G., Schwartz, P. B., Graham, M., Lee, L. M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1253659 · Cited by 6
“Dysregulation of mRNA translation is a major feature of neoplasia and stem cell maintenance (77 – 79).”
BackgroundShosaku, J. (2017) · Immunology · doi:10.1111/imm.12840 · Cited by 6
High-Throughput Screening for Protein Synthesis Inhibitors Targeting Aminoacyl-tRNA Synthetases
Kong, J., Fang, P., Madoux, F., Spicer, T., Scampavia, L. D., Kim, S., & Guo, M. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217734128 · Cited by 6
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Spatial protein and RNA analysis on the same tissue section using MICS technologyPreprint
Neil, E., Park, D., Hennessey, R. C., DiBiasio, E. C., DiBuono, M., Lafayette, H., Lloyd, E., Lo, H., Femel, J., Makrigiorgos, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.27.564191 · Cited by 6
Wang, J., Gao, C., Zhang, J., Luo, H., Dai, S., & Wang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1547794 · Cited by 5
Cyran, A. M., Kleinegger, F., Naß, N., Naumann, M., Haybaeck, J., & Arens, C. (2023) · Cancers · doi:10.3390/cancers15225350 · Cited by 5
“Its dysregulation is a hallmark of cancer and leads to abnormal proliferation, angiogenesis, metabolic changes, and patient survival [12].”
BackgroundN6-methyladenosine in 28S rRNA promotes oncogenic mRNA translation and tyrosine catabolism
Chen, B., Li, L., Huang, Y., Ma, J., Ji, F., Chen, Y., Wu, L., & Peng, H. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115139 · Cited by 5
Heffner, A. L., & Rouault, T. A. (2025) · Viruses · doi:10.3390/v17020256 · Cited by 5
“However, during coronavirus infection, cellular mRNAs are translated at a much lower frequency, and prior research has shown that housekeeping proteins are much less affected by eIF4F inhibition than viral proteins or oncogenes [184].”
Lister, K. C., Wong, C., Cai, W., Uttam, S., Stecum, P., Rodrigues, R., Hooshmandi, M., Brown, N., Fan, J., Francois-Saint-Cyr, N., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci180190 · Cited by 3
El‐Kadi, S. W., Chen, Y., McCauley, S. R., Seymour, K. A., Johnson, S., & Rhoads, R. P. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00704.2017 · Cited by 5
“Translation initiation is the first and tightly regulated ratelimiting step in protein synthesis and involves the assembly of a functional 43S preinitiation complex (5).”
BackgroundInfluentialNaha, S., Govindaiah, S., Sreenivasa, S., Prakash, J. K., & Velmathi, S. (2020) · ChemistrySelect · doi:10.1002/slct.202003025 · Cited by 5
CRISPR-Based Screen Links an Inhibitor of Nonsense-Mediated Decay to eIF4A3 Target Engagement
Cencic, R., Naineni, S. K., Pugsley, L., Sénéchal, P., Sahni, A., & Pelletier, J. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00253 · Cited by 5
Self-citationQuantitative Comparisons of Translation Activity by Ribosome Profiling with Internal Standards
Wang, Y. J., & Gilbert, W. V. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1150-0_5 · Cited by 5
Shin, S., Nicolle, R., Jean, C., Samain, R., Ayadi, M., Raffenne, J., Brunel, A., Solórzano, J., Neuzillet, C., Joffre, C., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.05.117 · Cited by 5
Frosi, Y., Ng, S., Lin, Y., Jiang, S., Ramlan, S. R., Lama, D., Verma, C. S., Asial, I., & Brown, C. J. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00099g · Cited by 5
“Additionally, small molecules and peptides can be used to target the interface between eIF4G and eIF4E.(15,21,22)”
BackgroundMethodZhao, H., Datta, S., & Duan, Z.-H. (2023) · Bioinformatics and Biology Insights · doi:10.1177/11779322231152972 · Cited by 5
Modulation of Reoviral Cytolysis (II): Cellular Stemness
Bourhill, T., Rohani, L., Kumar, M., Bose, P., Rancourt, D. E., & Johnston, R. N. (2023) · Viruses · doi:10.3390/v15071473 · Cited by 5
“However, tests of this model yielded conflicting results and the exact mechanisms co-ordinating RAS activation and PKR signalling in promoting reoviral replication [35] and the general control of protein synthesis [44,45] remain unclear.”
ResultTranslational control in the naked mole-rat as a model highly resistant to cancer
Maldonado, G., & Hernández, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188455 · Cited by 5
Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
Buono, R., Al-Haddad, M., & Fruman, D. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1162694 · Cited by 5
Wu, L. M. N., Oblinger, J. L., Xin, D. E., Rao, R., Zhang, F., Adam, M., Lopez‐Nunez, O. F., Szabo, S., von Allmen, D., Chang, L., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec6749 · Cited by 4
“Elevated levels of eIF4F components are correlated with higher tumor grade and with metastasis ( 63 ).”
Lee, Y. S., Good, J., Awais, N., Eschle, B. K., Lineberry, M. S., Lin, J., Wunderlich, M., Thibodeau, J., Edwards, H. J., Teo, J. L., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100202 · Cited by 4
“16,17 Among the main stages of eukaryotic translation, namely initiation, elongation, and termination, initiation is the rate-limiting step.”
Thankan, R. S., Thomas, E. B., Purushottamachar, P., Weber, D. J., Ramamurthy, V. P., Huang, W., Kane, M. A., & Njar, V. C. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240996 · Cited by 4
Widespread alteration of protein autoinhibition in human cancers
Holguin-Cruz, J. A., Bui, J. M., Jha, A., Na, D., & Gsponer, J. (2024) · Cell Systems · doi:10.1016/j.cels.2024.01.009 · Cited by 4
Kai, J., Kang, K., Jiang, Z., Xiong, F., & Wang, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33567 · Cited by 4
“Our prior investigation pinpointed eIF4E, a vital translational factor, especially significant for tumor cells [25], as a promoter of growth and survival in esophageal cancer cells [17].”
BackgroundReciprocal Dynamics of Metabolism and mRNA Translation in Tumor Angiogenesis
Lidonnici, J., & Oberkersch, R. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011284 · Cited by 4
“…complex (TC), composed of eIF2 (containing α -, β -, and γ -subunits), GTP and the initiator methionyl-tRNA (tRNA iMet ) associates with the minor ribosomal subunit (40S) and other initiation factors such as eIF1, eIF1A, eIF3 and eIF5 to form the 43S pre-initiation complex (43S PIC) [24,25].”
BackgroundTranslational regulation of SND1 governs endothelial homeostasis during stress
Han, Z., Yan, G., Jousma, J., Nukala, S. B., Amiri, M., Kiniry, S. J., Tabatabaei, N., Kwon, Y., Zhang, S., Rehman, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci168730 · Cited by 4
“Translational control is a key regulatory mechanism that controls protein abundance and thereby dictates identity and functions across cell types and tissues (1, 2).”
Nilewski, C., Michels, T., Packard, G. K., Xiang, A. X., Sprengeler, P. A., Eam, B., Fish, S., Thompson, P. A., Wegerski, C. J., Nevarez, A. J., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128111 · Cited by 4
Introduction to ribosome factory, origin, and evolution of translation
Kumar, V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816364-1.00002-0 · Cited by 4
Niehues, A., Bizzarri, D., Reinders, M. J. T., Slagboom, P. E., van Gool, A. J., van den Akker, E. B., Hoen, P. A. C. ’., & Consortia, T. B.-N. B. A. M. (2022) · BMC Genomics · doi:10.1186/s12864-022-08771-7 · Cited by 4
“Translation of mRNA is known to be dysregulated in cancers [28].”
BackgroundTranslatomics to explore dynamic differences in immunocytes in the tumor microenvironment
Guo, Y., Yan, S., & Zhang, W. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102037 · Cited by 4
“47,48 Compared with normal resting cells, unlimited proliferation is one of the characteristics of cancer cells.”
Naveed, M. (2017) · MOJ Proteomics & Bioinformatics · doi:10.15406/mojpb.2017.05.00177 · Cited by 4
The oncoprotein Myc controls the phosphorylation of S6 kinase and AKT through protein phosphatase 2A
Chellini, L., Monteleone, V., Lombari, M., Caldarola, S., & Loreni, F. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27309 · Cited by 4
“overexpression of a number of initiation factor observed in cancer cells.(30) Increasing evidence shows that Myc‐ driven oncogenesis is heavily dependent on its ability to drive cell growth processes including synthesis of translation apparatus.”
BackgroundCoupling Transcription and Translation via the Epitranscriptomic m6A Mark
Wang, K., & Yi, C. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00903 · Cited by 4
Network-based approaches for multi-omic data integration
Xiao, H. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.36964 · Cited by 4
ChIP-seq of plasma cell-free nucleosomes identifies cell-of-origin gene expression programs
Friedman, N., Sadeh, R., Sharkia, I., & Fialkoff, G. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3967253 · Cited by 4
Signaling dynamics during Vertebrate segmentation
Hubaud, A. (2016) · theses.fr (ABES) · doi:10.70675/3e224f29z216az47a5z848czfeede3c098a4 · Cited by 4
Shin, S., Nicolle, R., Jean, C., Samain, R., Ayadi, M., Raffenne, J., Brunel, A., Solorzano, J., Neuzillet, C., Joffre, C., et al. (2020) · doi:10.1101/2020.12.23.424227 · Cited by 3
The implication of non-AUG-initiated N-terminally extended proteoforms in cancer
Pancsa, R., Andreev, D. E., & Dean, K. A. (2025) · RNA Biology · doi:10.1080/15476286.2025.2498203 · Cited by 3
Pott, J., Kryvenko, V., & Vadász, I. (2026) · European Respiratory Review · doi:10.1183/16000617.0049-2025 · Cited by 3
“Furthermore, cancer research has demonstrated that the ribosomal landscape can serve as a pharmacological target [15, 16].”
Chen, J., Zheng, G., Wen, Y., Fang, F., Liu, Y., Liu, Z., Su, T., Lin, S., Li, S., Liao, J., et al. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01137-7 · Cited by 3
“…components, including eukaryotic initiation factors (eIFs) and ribosomal proteins (RPs), promotes tumor progression and therapeutic resistance [13, 14 ]. tRNA modifications rep - resent a pivotal regulatory layer wherein chemical alterations govern tRNA structural integrity, codon-anticodon…”
Hamadou, M. H., Alunno, L., Peroni, D., Pancher, M., Mazza, F., Venturelli, T., Belli, R., Dassi, E., Romanel, A., & Inga, A. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101535 · Cited by 3
“…with the growing evidence for unexpected complexity and variability in ribosome composition and function, these findings justify the growing interest in studying mRNA translation control in cancer and the opportunity for developing effective cancer therapies targeting translation initiation (45).”
Zhou, R., Yang, Q., Yang, Q., Yu, J., Zheng, J., Yan, H., Jiang, X., Chen, M., Liang, Z., Jia, Y., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174656 · Cited by 3
The human eIF4E:4E-BP2 complex structure for studying hyperphosphorylation
Zeng, J., Lu, C., Huang, X., & Li, Y. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp05736d · Cited by 3
Zhou, X., Cheng, S., Chen, Z., Zhang, J., Wang, J., Li, Q., & Zhou, X. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101109 · Cited by 3
Thelagathoti, R. K., Chandel, D. S., Jiang, C. Q., Tom, W. A., Krzyzanowski, G. D., Olou, A. A., & Fernando, M. R. (2025) · Cancers · doi:10.3390/cancers17213509 · Cited by 3
Prognostic Value of Malignant T Cell-Amplified Sequence 1 in Head and Neck Squamous Cell Carcinoma
Zhu, J., Wang, X., Shao, Z., Sun, W., & Wu, T. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0600 · Cited by 3
Yi, C., Liu, J., Zhao, S., Gong, D., Xu, B., Li, A., Bian, E., & Tian, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-67547-z · Cited by 3
“Both the increased efficiency of protein synthesis and the decreased fidelity of translation are associated with aberrant ribosome biogenesis, which may lead to tumorigenesis 30–32 .”
BackgroundPPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation
Sonenberg, N., Wang, P., Li, Z., Kim, S., Huang, H., Choi, J.-H., Xu, H., yang, C., Snape, A., Bermudez, S., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402755 · Cited by 3
“Thus, inhibiting their phosphorylation can potentially lead to cancer therapies (Silvera et al, 2010; Ruggero, 2013; Bhat et al, 2015; Pelletier et al, 2015; Siddiqui & Sonenberg, 2015). mTOR inhibitors (e.g., rapamycin analogs; rapalogs and TORKi; TOR kinase inhibitors) have shown only limited…”
Self-citationRibosomal rodeo: wrangling translational machinery in gynecologic tumors
Filipek, K., & Penzo, M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10234-2 · Cited by 3
“Release factor 1 (RF1), which enters the termination phase together with the RF3*GTP complex and provides the energy for RF1 accommodation in the A-site, recognizes the stop codon (7).”
BCR engagement in CLL: when translation goes wrong
Paggetti, J., & Moussay, E. (2016) · Blood · doi:10.1182/blood-2015-11-678623 · Cited by 3
“Translation is a process frequently dysregulated in tumors and constitutes a valuable target for the development of novel anticancer therapies.(4) Quiescent circulating CLL cells represent the most accessible population and are consequently more studied than CLL cells located in the bone marrow and lymph nodes (LNs).”
BackgroundModeling and Dynamic Behavior of eIF2 Dependent Regulatory System With Disturbances
Khan, M. F., Spurgeon, S. K., & Yan, X. (2018) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2018.2873027 · Cited by 3
“There are several reasons to investigate the stability of the eIF2 dependent regulatory system, such as, in drug design targeting particular complex to override the undesirable interaction while avoiding unintended targets is one of the attractive possibilities [15], [16].”
BackgroundThe RNPs of eukaryotic translation control
Fritz, S. E., & Boris‐Lawrie, K. (2015) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 3
Lintner, N. G., McClure, K. F., Petersen, D. N., Londregan, A. T., Piotrowski, D. W., Wei, L., Xiao, J., Bolt, M. W., Loria, P. M., Maguire, B. A., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.1002628 · Cited by 3
Herrmannová, A., Jelínek, J., Pospíšilová, K., Kerényi, F., Vomastek, T., Watt, K., Brábek, J., Mohammad, M. P., Wagner, S., Topisirović, I., et al. (2024) · eLife · doi:10.7554/elife.95846.2 · Cited by 3
Ali, S., Ren, S., Agsaoa, A., Mir, S., & Mir, M. A. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110173 · Cited by 2
“This mechanism has shown ef fi cacy against various RNA viruses, including hepatitis E virus (46, 48, 49).”
Zhang, H., Yu, S., Wang, Y., Wu, S., Shan, C., & Zhang, W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157331 · Cited by 2
“Among these approaches, targeting translational machinery components represents an emerging frontier, which exploits cancer cells’ heightened dependence on protein synthesis for survival and adaptation [11–14].”
The many ways to inhibit translation by Sorafenib in liver cancer cells
Contreras, L., Ricciardi, S., Biffo, S., Muntané, J., & de la Cruz, J. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05391-z · Cited by 2
“This establishes a positive feedforward loop, whereby c-Myc increases the levels of these translation factors, which in turn promote the translation of the c-Myc mRNA ( e.g. [24, 58]).”
Yaghmayee, S., Tabibian, S. S., dashtestani, Z., Eslami, M., Mahooti, M., Hemati, S., Sanami, S., & Pajand, O. (2026) · Archives of Microbiology · doi:10.1007/s00203-025-04642-3 · Cited by 2
“Three main pathways contribute to this step, including: RAS-RAF-MEK-ERK, PI3K-Akt-mTOR, and p38 MAPK pathway (Bhat et al. 2015).”
Nagasubramanian, K., Vincent, P., Gupta, K. K., & Chandran, S. A. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00759-1 · Cited by 2
Pharmacological landscape of carbolines: a holistic view
Zhang, Y., Wu, F., Rehman, M. U., & Long, S. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00057f · Cited by 2
Hermán‐Sánchez, N., Fernández‐Barrena, M. G., Alañón-Martínez, P. E., Uriarte, I., Agami, R., Luque, R. M., Avila, M. A., Rodríguez‐Perálvarez, M., Lopez-Canovas, J. L., & Gahete, M. D. (2026) · Hepatology · doi:10.1097/hep.0000000000001736 · Cited by 2
Hu, X., Xie, J., Li, Y., Li, K., & Wang, B. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189602 · Cited by 2
P5CS represses tumor progression via inhibiting assembly of 48S pre-translation initiation complex
Zhang, Q., Cheng, S., Gu, Y., Pan, Y., Zhu, X., Sun, J., Wen, Y., & Gao, S. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.05.011 · Cited by 2
A Systems Biology Approach to Understand the Racial Disparities in Colorectal Cancer
Nwaokorie, A., Kölch, W., & Fey, D. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0464 · Cited by 2
“EIF4Ephosphorylationinresponsetoextracellularstimulation leads to uncontrolled translation and proliferation and inhibits apoptosis (63).”
BackgroundEiken, A. P., Smith, A. L., Skupa, S. A., Schmitz, E. G., Rana, S., Singh, S., Kumar, S., Mallareddy, J. R., de Cubas, A. A., Krishna, A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0071 · Cited by 2
“A growing body of evidence suggests that cancer cells’ reliance on height-enedproteinsynthesisstemsfromirregulartranslationalregulationpartiallyby mTORC1 phosphorylation of 4E-BP1 (32, 34).”
InfluentialDesign and development of a series of 4-(piperazin-1-yl)pyrimidines as irreversible menin inhibitors
Luo, M., Ye, Y., Tang, L., Kan, W., Chen, L., Li, S., Li, S., Zhou, Y., Li, J., Xiong, B., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116918 · Cited by 2
Possible herbal medications and human cancer targets
(2025) · Global Journal of Basic Science · doi:10.63454/jbs20000008 · Cited by 2
Zhou, H., Wu, M., Wu, K., Tan, Q., Xu, X., Wang, M., Sun, L., Tu, Y., Zheng, W., Zhu, Y., et al. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100111 · Cited by 2
Weaning Date for Spring Calving Cows Grazing Sandhills Range
Ciminski, L. A., Adams, D. C., Klopfenstein, T. J., Clark, D., Applegarth, A., Musgrave, J. A., & Sandberg, R. (2002) · Lincoln (University of Nebraska) · Cited by 2
The VHL short variant involves in protein quality control
Liu, Y., Yang, H., Zuo, F., & Chen, L. (2016) · Gene · doi:10.1016/j.gene.2016.05.027 · Cited by 2
The Unfolded Protein Response in Triple-Negative Breast Cancer
Zhao, N., Peng, F., & Chen, X. (2019) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-05067-2_7 · Cited by 2
eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability
Casacuberta‐Serra, S., González-Larreategui, Í., & Soucek, L. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-682 · Cited by 2
“Of note, eIF4F controls the translation of mRNAs that encode proteins that induce proliferation, survival, metastasis, and immune evasion (13,14).”
BackgroundJuxtacap Nucleotide Sequence Modulates eIF4E Binding and TranslationPreprint
Keys, H. R., & Sabatini, D. M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/165142 · Cited by 2
“eIF4E is overexpressed in several types of cancer (reviewed in (16)), experimental overexpression of eIF4E in cells leads to oncogenic transformation in vitro (17), and overexpression in mice leads to increased tumor incidence (18).”
BackgroundHerzog, L.-O. (2020) · eScholarship (California Digital Library) · Cited by 2
Moore, M., Pardo, L., Mitchell, L. E., Schmidt, T., Waldron, J. A., May, S., Müller, M., Smith, R. C. L., Strathdee, D., Bryson, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.16.553544 · Cited by 2
“Several of cancer’s aggressive characteristics depend on the ability of oncogenic signalling to re-program mRNA-translation(1, 2).”
BackgroundeIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancersPreprint
Waldron, J. A., Kanellos, G., Smith, R. C. L., Knight, J. R. P., Munro, J., Alexandrou, C., Vlahov, N., Pardo, L., Moore, M. H., Gillen, S. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566546 · Cited by 2
Herrmannová, A., Jelínek, J., Pospíšilová, K., Kerényi, F., Vomastek, T., Watt, K., Brábek, J., Mohammad, M. P., Wagner, S., Topisirović, I., et al. (2024) · eLife · doi:10.7554/elife.95846.1 · Cited by 2
Yu, L., Ajiro, M., Lobanov, A. V., Cam, M. C., Majerčiak, V., Karim, B. O., Gotte, D., Deng, C., Lowy, D. R., Webster, N. J. G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643315 · Cited by 2
“Eif4a2 gene has 12 exons and its exon 11 is a “poison exon”.”
InfluentialNallapareddy, M. V., Craighero, F., Worpenberg, L., Naef, F., Gobet, C., & Vandergheynst, P. (2025) · Communications Biology · doi:10.1038/s42003-025-09092-7 · Cited by 1
“With important advances such as theTransformerarchitecture 19 , deep learningisincreasinglybecomingcentraltogenomicresearch 20 .”
Quantitative Analysis of Global Protein Stability Rates in Tissues
McClatchy, D. B., Gao, Y., Lavallée-Adam, M., & Yates, J. R. (2019) · doi:10.1101/520494 · Cited by 1
“initiation factors is observed in a wide range of cancers[40].”
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Frosi, Y., Ramlan, S. R., & Brown, C. J. (2020) · Journal of Visualized Experiments · doi:10.3791/60850 · Cited by 1
Tumor metabolic reprogramming in therapeutic resistance
Siegel, P. M., & Ursini‐Siegel, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00005-x · Cited by 1
Thelagathoti, R. K., Jiang, C., Chandel, D. S., Tom, W. A., Sarmiento, C., Olou, A. A., Krzyzanowski, G. D., & Fernando, M. R. (2026) · Bioengineering · doi:10.3390/bioengineering13060597 · Cited by 1
“A coordinated cluster of translational machinery terms, including the eukaryotic 80S initiation complex, 90S preribosome assembly, and translation elongation factor complex, is consistent with mTORC1-driven translational upregulation in aggressive ovarian carcinoma [62,63].”
Altered neuronal start codon stringency favors cap-independent repeat-associated non-AUG translation
Wieland, C. M., Wright, S. E., Willey, S., Purwar, I., Grudzien, S., Krans, A., Laimon-Thomson, E. L., Asher, M. J., Isaacs, A. M., Garner, A. L., et al. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag880 · Cited by 1
Klapp, V., Gumustekin, O., Paggetti, J., Moussay, E., & Largeot, A. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.06.006 · Cited by 1
Gan, B. H., Lee, L. H., Takeda, R., Yasin, M., Teneggi, V., Ethirajulu, K., Yeo, P., Umrani, D., Pendharkar, V., Lim, D. W. T., et al. (2024) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079248 · Cited by 1
Lai, X., Pan, G., Feng, X., Zhang, J., Li, Y., Zhao, S., Lin, Z., Feng, Y., Bao, W., Yang, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202520625 · Cited by 1
Wang, G., Gao, X., Zhang, H., Hu, K., Feng, Q., Liu, Y., Hu, C., Guo, S., Yu, D., Chang, S., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03706-y · Cited by 1
Huang, Q.-Y., He, M., Cao, T., Chen, C., Zhou, P., Liu, Z. H., & Xie, R. (2026) · Scientific Reports · doi:10.1038/s41598-026-50074-4 · Cited by 1
“Key translational factors such as eIF4E, eEF2, and mTORC1 have already emerged as potential anticancer targets 61 .”
Horochowska, M., Jakubczyk, E., & Ussowicz, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1832877 · Cited by 1
“…R98S – driven BCL-2 dependence). disruption; MNK inhibitors (e.g., tomivosertib) show preclinical activity in AML, particularly in combination with venetoclax (30). eIF4A, the DEAD-box RNA helicase component of eIF4F that unwinds structured 5 ′ UTRs to enable scanning, is another compelling target.”
Raghavan, P. R. (2026) · Medical Research Archives · doi:10.18103/mra.2026.0447 · Cited by 1
Shooting the messenger (RNA) in B-cell lymphoma
Yeomans, A., & Packham, G. (2016) · Blood · doi:10.1182/blood-2015-12-685156 · Cited by 1
Effects of tumor biobank storage on polysome stability
Lupinacci, F. C. S., Ferreira, E. N., Roffé, M., Bellato, H. M., Carraro, D. M., & Hajj, G. N. M. (2019) · Applied cancer research/Applied Cancer Research · doi:10.1186/s41241-019-0077-0 · Cited by 1
Salvi, N., Papadopoulos, E., Blackledge, M. J., & Wagner, G. (2016) · Angewandte Chemie · doi:10.1002/ange.201603254 · Cited by 1
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.